Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 797 across all filing types
Latest filing 2023-04-05 Annual Report
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Annual Report 2022
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2022' and contains extensive sections typical of a full annual report, including financial statements, auditor's report, CEO statement, business overview, risk management, corporate governance, remuneration report, and forward-looking statements. It references the fiscal year 2022 and includes detailed financial and operational information. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-04-05 English
6-K
Regulatory Filings
2023-03-27 English
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
Regulatory Filings Classification · 95% confidence The document is a press release dated March 24, 2023, announcing that the US FDA has approved Joenja® (leniolisib) for APDS. It details the drug's indication, clinical trial results, safety information, and future commercial plans (launch expected early April). It also mentions an upcoming investor conference call on March 27th. This content structure—a major corporate event announcement (drug approval) with financial and operational context, issued via press release—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on a major positive operational/product milestone (FDA approval) rather than just financial figures (ER) or a general regulatory update (RNS), and it is not a full report (like 10-K or IR), it best fits the category for initial announcements of key results or events. Given the focus on the approval and immediate commercial plans, 'Earnings Release' (ER) is often used broadly for major positive news releases, but 'Regulatory Filings' (RNS) is a safer fallback for non-standard announcements. However, the content is a definitive announcement of a major corporate event (FDA approval) and includes quotes from management and key stakeholders, which strongly aligns with the function of an Earnings Release or a significant corporate update. Since there is no specific category for 'Drug Approval Announcement', and it is not a transcript (CT), presentation (IP), or a formal regulatory filing form, I will classify it based on its function as a major, time-sensitive corporate announcement. Given the options, 'ER' (Earnings Release) is often used for major periodic announcements, but this is a specific product milestone. 'RNS' (Regulatory Filings) is the general catch-all. Given the high significance and the structure resembling a major update, I will lean towards RNS as the most appropriate general regulatory/corporate announcement category when a specific product/approval category is missing, as it is a formal announcement to the market about a significant event. Revisiting the definitions: ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. RNS is 'General regulatory announcements and fallback category for miscellaneous filings'. This fits well as a significant, non-standard corporate announcement. However, the document also announces a conference call for investors and analysts ('Pharming organiseert op 27 maart om 14:00 CET een conference call voor investeerders en analisten'). This strongly suggests it functions as an Earnings Release or an event announcement related to corporate performance/outlook. Since it is a major announcement that sets the stage for future performance, and it is not a transcript of that call, ER is a plausible fit if interpreted broadly as a major corporate update, but RNS remains the most accurate fallback for a non-financial, non-meeting-related regulatory announcement. I will select RNS as the most accurate fit for a press release announcing a major regulatory/product milestone that doesn't fit the financial reporting categories (10-K, IR, ER, MRQ).
2023-03-27 English
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
Regulatory Filings Classification · 95% confidence The document is a press release titled "Pharming announces US FDA approval of Joenja® (leniolisib) for APDS". It details a significant regulatory event (FDA approval), provides clinical trial results, discusses commercial launch plans, and includes forward-looking statements and important safety information. This format is characteristic of an initial announcement of financial or material corporate news, specifically related to product approval and commercialization readiness. It is not a comprehensive annual report (10-K), a quarterly report (IR), a transcript (CT), or a proxy statement (DEF 14A). Since it is the initial announcement of key financial/operational results (FDA approval leading to potential revenue), it best fits the Earnings Release (ER) category, which often encompasses major corporate milestones announced outside of standard quarterly reporting cycles, or it could be classified as a general Regulatory Filing (RNS) if ER is strictly limited to quarterly financials. Given the magnitude of an FDA approval announcement, which drives future earnings, ER is a strong candidate, but RNS is the most appropriate fallback for significant, non-standard regulatory news. However, looking at the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is an announcement of a major operational/regulatory milestone that directly impacts future financial performance. Since there is no specific category for 'Drug Approval Announcement', and it is a major announcement of a key event, it functions similarly to an earnings highlight release. Given the context of financial reporting databases, major operational news like this is often grouped with ER or RNS. Since it is a specific, material announcement, RNS (General regulatory announcements and fallback) is the safest classification if ER is too narrow, but ER often captures the 'key highlights' of a period's performance drivers. I will lean towards RNS as it is a specific regulatory event announcement that isn't strictly quarterly financial results.
2023-03-27 English
6-K
Regulatory Filings
2023-03-16 English
Pharming Group reports financial results for full year 2022
Earnings Release Classification · 99% confidence The document explicitly states it presents the "preliminary (unaudited) financial report for the full year ended December 31, 2022." It contains detailed financial highlights (revenues, operating profit, cash flows) and extensive commentary on business strategy, pipeline development (leniolisib, OTL-105), and regulatory milestones for the full fiscal year. This structure—a comprehensive review of the entire fiscal year's performance, including preliminary financial figures—is characteristic of an Annual Report, which corresponds to the 10-K filing type in the US context, or a comprehensive Annual Report (AR) if it's not the official SEC filing. Given the comprehensive nature covering the full year and including financial results, it aligns best with the Annual Report category (10-K). Although it mentions 'preliminary (unaudited)', the content depth suggests it is the primary annual financial disclosure document, which is typically classified as 10-K. FY 2022
2023-03-16 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.